Dr. Nathan J. Cleaver, DO
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- At Still University of Health Sciences, College of Osteo Med, Kirksville (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 1,825
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: At Still University of Health Sciences, College of Osteo Med, Kirksville
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
GA license 76962 · MO license 2015008267 -
Dermatopathology Physician
GA license 76962 -
MOHS-Micrographic Surgery Physician
GA license 76962
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Cleaver Medical Group Dermatology Inc (13 clinicians)
- Cleaver Dermatology PC (6 clinicians)
- Dalton Dermatology and Day Spa, LLC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,825
- Services billed
- 11,637
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 2,152 | 286 |
| Pathology examination of tissue using a microscope, intermediate complexity | 1,520 | 859 |
| Established patient office or other outpatient visit, 20-29 minutes | 769 | 518 |
| Destruction of precancer skin growth, 1 growth | 417 | 330 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 405 | 314 |
| Biopsy of related skin growth, first growth | 357 | 293 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 240 | 157 |
| Destruction of precancer skin growth, 15 or more growths | 180 | 132 |
| Biopsy of related skin growth, each additional growth | 169 | 99 |
| New patient office or other outpatient visit, 30-44 minutes | 154 | 154 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 78 payments worth $23,530 in total to this clinician.
| Sanofi US Services Inc. | $10,036 |
|---|---|
| Sun Pharmaceutical Industries Inc. | $8,280 |
| UCB, Inc. | $2,138 |
| Janssen Biotech, Inc. | $1,554 |
| AbbVie Inc. | $440 |
| Genzyme Corporation | $199 |
| Arcutis Biotherapeutics, Inc. | $156 |
| Organon LLC | $147 |
| Consulting Fee | $20,386 |
|---|---|
| Food and Beverage | $1,971 |
| Travel and Lodging | $1,069 |
| Education | $103 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sun Pharmaceutical Industries Inc. Feb 28, 2025 | Consulting Fee LEVULAN KERASTICK · Dermatology | $7,000 |
| Sanofi US Services Inc. Mar 28, 2025 | Consulting Fee | $5,162 |
| Sanofi US Services Inc. Aug 28, 2025 | Consulting Fee | $4,015 |
| UCB, Inc. Jun 10, 2025 | Consulting Fee Bimzelx · Immunology | $1,950 |
| Janssen Biotech, Inc. Jun 14, 2025 | Consulting Fee TREMFYA · Immunology | $1,400 |
| Sanofi US Services Inc. Feb 27, 2025 | Consulting Fee | $860 |
| Sun Pharmaceutical Industries Inc. Feb 27, 2025 | Travel and Lodging LEVULAN KERASTICK · Dermatology · travel to Dallas, TX · in-kind | $682 |
| Sun Pharmaceutical Industries Inc. Feb 27, 2025 | Travel and Lodging LEVULAN KERASTICK · Dermatology · travel to Dallas, TX · in-kind | $315 |
| Janssen Biotech, Inc. Jun 13, 2025 | Education TREMFYA · Immunology · in-kind | $94.99 |
| Sun Pharmaceutical Industries Inc. Feb 27, 2025 | Travel and Lodging LEVULAN KERASTICK · Dermatology · travel to Dallas, TX · in-kind | $72.00 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Sanofi US Services Inc. Aug 28, 2025 | Consulting Fee | $4,015 |
| Janssen Biotech, Inc. Jun 14, 2025 | Consulting Fee TREMFYA · Immunology | $1,400 |
| Janssen Biotech, Inc. Jun 13, 2025 | Education TREMFYA · Immunology · in-kind | $94.99 |
| UCB, Inc. Jun 10, 2025 | Consulting Fee Bimzelx · Immunology | $1,950 |
| Sanofi US Services Inc. Mar 28, 2025 | Consulting Fee | $5,162 |
| Genzyme Corporation Mar 18, 2025 | Education in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $8.25 |
| Sun Pharmaceutical Industries Inc. Feb 28, 2025 | Consulting Fee LEVULAN KERASTICK · Dermatology | $7,000 |
| Sanofi US Services Inc. Feb 27, 2025 | Consulting Fee | $860 |
| Sun Pharmaceutical Industries Inc. Feb 27, 2025 | Travel and Lodging LEVULAN KERASTICK · Dermatology · travel to Dallas, TX · in-kind | $682 |
| Sun Pharmaceutical Industries Inc. Feb 27, 2025 | Travel and Lodging LEVULAN KERASTICK · Dermatology · travel to Dallas, TX · in-kind | $315 |
| Sun Pharmaceutical Industries Inc. Feb 27, 2025 | Travel and Lodging LEVULAN KERASTICK · Dermatology · travel to Dallas, TX · in-kind | $72.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 3 companies. The companies reported $439,932 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie Inc. · Active, not recruiting · NCT06468228 - A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie Inc. - A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis
Incyte Corporation - Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Sanofi US Services Inc. · Active, not recruiting · NCT05492578 - A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie Inc. · Recruiting · NCT06012240 - M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie Inc. - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Sanofi US Services Inc. · Completed · NCT06224348 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
AbbVie Inc. · Active, not recruiting · NCT06118411
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.